Antihypertensive Therapeutics Market Size, Share, Growth & Analysis Report 2020: Radiant Insights, Inc
GBI Research, the leading business intelligence provider, has released its latest research, ''Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries'', which provides in-depth analysis of hypertension therapeutics market within the eight major geographies of the US, the top five European countries (the UK, France, Germany, Spain and Italy), Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. Browse Full Report With TOC @ http://www.radiantinsights.com/research/antihypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017.
GBI Research, the leading business intelligence provider, has released its latest research, ''Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries'', which provides in-depth analysis of hypertension therapeutics market within the eight major geographies of the US, the top five European countries (the UK, France, Germany, Spain and Italy), Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
Browse Full Report With TOC @ http://www.radiantinsights.com/research/antihypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries
The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
6.1.2 Takeda Pharma Enters into Licensing Agreement with Arbor Pharma for Edarbi and Edarbyclor 57<br />
6.1.3 Lorus <strong>Therapeutics</strong> Enters into Licensing Agreement with Zor Pharma 57<br />
6.1.4 Nippon Shinyaku Signs Licensing Agreement with Eli Lilly 57<br />
6.2 Co-development Deals 58<br />
6.2.1 AnGes Enters into Co-development Agreement with BioLeaders for Hypertension Vaccine 59<br />
6.2.2 Takeda Enters into Co-development Agreement with Covance 59<br />
6.2.3 Boehringer Ingelheim Enters into an Agreement with Vitae Pharma 59<br />
6.2.4 NicOx Expands Research Collaboration with Merck 59<br />
Browse Full <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/antihypertensivetherapeutics-in-major-developed-markets-to-<strong>2020</strong>-increased-uptake-of-combination-therapies-tooffset-effects-of-key-patent-expiries<br />
7 Appendix 60<br />
7.1 <strong>Market</strong> Forecasts to <strong>2020</strong> 60<br />
7.2 All Pipeline Drugs by Phase 63<br />
7.2.1 Discovery 63<br />
7.2.2 Preclinical 64<br />
7.2.3 Phase I 66<br />
7.2.4 Phase II 74<br />
7.2.5 Phase III 77<br />
7.3 Abbreviations 82<br />
7.4 References 84<br />
7.5 Methodology 87<br />
7.5.1 Coverage 87<br />
7.5.2 Secondary Research 88<br />
7.5.3 Primary Research 88<br />
7.5.4 Therapeutic Landscape 88<br />
7.5.5 Geographical Landscape 91
Change language